Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > NanoViricides, Inc. Participated In WHO Meeting On Dengue Therapeutics

Abstract:
Company to File Annual Report Shortly

NanoViricides, Inc. Participated In WHO Meeting On Dengue Therapeutics

WEST HAVEN, CT | Posted on October 20th, 2008

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that it participated in a meeting of international experts on Dengue Therapeutics held by the Special Programme for Research and Training in Tropical Diseases (TDR), of the World Health Organization (WHO), in Geneva, Switzerland on October 2, 2008.

"Viral load reduction was clearly recognized as an important goal in Dengue treatment at this meeting. Nanoviricides are well suited for Dengue treatment because they are specifically designed for viral load reduction. We believe that our novel nanomedicine-based direct antiviral approach will be of great value in combating the Dengue viruses," said Anil R. Diwan, PhD, President of the Company, who participated in the meeting.

In another note, the Company clarified that the deadline for filing its Annual Report on Form 10-K, within the thirty day grace period allowed, is October 29, 2008. The Company, its counsel, public auditors and internal accountants, are committed to finalizing and filing the report accordingly. The Company expects to file the Annual Report shortly. When the Company files its annual report, the "E" will be removed from the Company's symbol, changing it back to the normal NNVC. The presence of an "e" (i.e. NNVCE) does not constitute a trading halt or delisting of the company's stock. It resulted from the original filing date for the annual report being exceeded.

NIAID experts see dengue as an important potential threat to the US public health (http://www.nih.gov/news/pr/jan2008/niaid-08.htm). The mosquito vectors that carry dengue viruses have been found in 36 or more states. Human infections in southern states have also been reported. Worldwide, dengue is among the most important reemerging infectious diseases with an estimated 50 to 100 million annual cases and 22,000 deaths. Dengue has become endemic in many tropical countries. (www.iht.com/articles/2008/05/15/healthscience/13brod.php).

Dengue fever is caused by one of four dengue virus types. Most people when they get the first infection have mild disease. A second infection with a different type of dengue virus can lead to a severe and life-threatening form of dengue disease, called severe dengue or dengue hemorrhagic fever. Thus people who have had a primary infection are primed for a severe form of the disease. Dengue severity is expected to continue to increase worldwide.

There are currently no drug treatments or vaccines against dengue.

####

About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

For more information, please click here

Contacts:
NanoViricides, Inc.
Amanda Schuon
310-550-7200

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Industrial Nanotech, Inc. Announces Next Large Order from the Oil and Gas Industry March 26th, 2015

Quantum compute this -- WSU mathematicians build code to take on toughest of cyber attacks: Revamped knapsack code offers online security for the future March 26th, 2015

Thousands of atoms entangled with a single photon: Result could make atomic clocks more accurate March 26th, 2015

Square ice filling for a graphene sandwich March 26th, 2015

Nanomedicine

Graphene reduces wear of alumina ceramic March 26th, 2015

Application of Graphene Oxide in Body Implants in Iran March 26th, 2015

Nanorobotic agents open the blood-brain barrier, offering hope for new brain treatments March 25th, 2015

Nanotechnology in Medical Devices Market is expected to reach $8.5 Billion by 2019 March 25th, 2015

Announcements

Industrial Nanotech, Inc. Announces Next Large Order from the Oil and Gas Industry March 26th, 2015

Quantum compute this -- WSU mathematicians build code to take on toughest of cyber attacks: Revamped knapsack code offers online security for the future March 26th, 2015

Thousands of atoms entangled with a single photon: Result could make atomic clocks more accurate March 26th, 2015

Square ice filling for a graphene sandwich March 26th, 2015

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers

Graphene reduces wear of alumina ceramic March 26th, 2015

Quantum compute this -- WSU mathematicians build code to take on toughest of cyber attacks: Revamped knapsack code offers online security for the future March 26th, 2015

Thousands of atoms entangled with a single photon: Result could make atomic clocks more accurate March 26th, 2015

Square ice filling for a graphene sandwich March 26th, 2015

Events/Classes

LAMDAMAP 2015 hosted by the University March 26th, 2015

SUNY POLY CNSE to Host First Ever Northeast Semi Supply Conference (NESCO) Conference Will Connect New and Emerging Innovators in the Northeastern US and Canada with Industry Leaders and Strategic Investors to Discuss Future Growth Opportunities in NYS March 25th, 2015

NNI Publishes Workshop Report Assessing the Status of EHS Risk Science: Report examines progress three years after the release of the 2011 NNI EHS Research Strategy March 23rd, 2015

EEE Photonics Society’s Fourth Annual Optical Interconnects Conference Seeks to Bring Together the Latest Advanced Optical Interconnect Technologies, Systems & Architectures for the Next Generation of Supercomputers & Datacenters March 23rd, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE